Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4626 Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Introduction: The efficacy and time to progression (TTP) following peptide receptor radionuclide therapy (PRRT) for pancreatic neuroendocrine tumours varies widely.

Conference:

Presenting Author: Papantoniou D

Authors: Tiensuu Janson E, Fröss-Baron K, Grönberg M, Ziolkowska B,

Keywords: prrt, pancreatic neuroendocrine tumour, predictive model,

#4551 Characterisation and management of neuroendocrine tumours: Findings from a prospective study in Algeria

Introduction: Gastrointestinal neuroendocrine tumours are characterised by varied clinical presentations and behaviours. Their increasing incidence highlights the need for better understanding and management strategies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: Neuroendocrine neoplasm, Observational Study, Treatment Outcomes,

#4510 Follow-up analysis of group nutritional education in patients with neuroendocrine neoplasms (GEDNEN Course): A novel approach with proven acceptability

Introduction: Structured group education demonstrates improved outcomes in peri-operative health optimisation and diabetes mellitus. We devised and delivered a novel in person nutrition/dietary education programme for patients with neuroendocrine neoplasms (NENs) at the Sheffield ENETS Centre of Excellence.

Conference:

Presenting Author: Munir A

Authors: Wen Loh E, Walsh E, Bisson H, Ahmed Z, Dancyger-Stevens L,

Keywords: Group Education, Nutrition, Neuroendocrine Neoplasm, Novel Tool,

#4402 Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomised study of cessation of somatostatin analogues after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours

Introduction: After progressing on somatostatin analogues (SSA), patients with somatostatin receptor positive gastroenteropancreatic (GEP) NETs often receive PRRT. It is unclear whether current practice of continuing SSA after commencing PRRT is beneficial, especially in non-functioning NETs.

Conference:

Presenting Author:

Authors: Burge M, Wyld D, Pattison D, Loree J, Goodwin R,

Keywords: Somatostatin analogue, peptide receptor radionuclide therapy, gastroenteropancreatic, neuroendocrine, non-functioning, cessation, Australasian Gastro-Intestinal Trials Group (AGITG), Canadian Cancer Trials Group (CCTG),